Choroidal neovascularization in pathological myopia

Progress in Retinal and Eye Research

Volumn 31, Issue 5, 2012, Pages 495-525

  Neelam, Kumari ^a,b   Cheung, Chiu Ming Gemmy ^c   Ohno Matsui, Kyoko ^d   Lai, Timothy Y Y ^e   Wong, Tien Y ^b,c,f  

^a KHOO TECK PUAT HOSPITAL   (Singapore)

^b SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^c SINGAPORE NATIONAL EYE CENTRE   (Singapore)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Chorioretinal atrophy; Choroidal neovascularization; Laser photocoagulation; Pathological myopia; Photodynamic therapy; Vascular endothelial growth factor inhibitors

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; PEGAPTANIB; PLACEBO; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN INHIBITOR; VERTEPORFIN;

ASIAN; AUTOFLUORESCENCE IMAGING; CATARACTOGENESIS; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENDOPHTHALMITIS; HEART INFARCTION; HUMAN; HYPERTENSION; HYPERTHERMIC THERAPY; INDOCYANINE GREEN ANGIOGRAPHY; INTRAOCULAR PRESSURE; LASER COAGULATION; MORBIDITY; MYOPIA; OPTICAL COHERENCE TOMOGRAPHY; OPTIMAL DRUG DOSE; PATHOGENESIS; PHOTODYNAMIC THERAPY; PIGMENT EPITHELIUM; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RETINA DETACHMENT; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA TRANSLOCATION; REVIEW; RISK FACTOR; SIDE EFFECT; SOCIOECONOMICS; SUBRETINAL NEOVASCULARIZATION; TERATOGENICITY; THROMBOEMBOLISM; TREATMENT PLANNING; VISUAL IMPAIRMENT; VITREOUS HEMORRHAGE;

ANGIOGENESIS INHIBITORS; CHOROIDAL NEOVASCULARIZATION; HUMANS; LASER COAGULATION; MYOPIA; PHOTOCHEMOTHERAPY; PROGNOSIS; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTORS; VISUAL ACUITY;

EID: 84863836311     PISSN: 13509462     EISSN: 18731635     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2012.04.001     Document Type: Review

References (266)

1. Anon Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report 1. Arch. Ophthalmol. 1999, 117:1329-1345.
2. Adelberg D.A., Del Priore L.V., Kaplan H.J. Surgery for subfoveal membranes in myopia, angiod streaks, and other disorders. Retina 1995, 15:198-205.
3. Arias L., Planas S., Prades S., Caminal J.M., Rubio M., Pujol O., Roca G. Intravitreal bevacizumab (Avastin) for choroidal neovascularization secondary to pathological myopia: 6 month results. Br. J. Ophthalmol. 2008, 92:1035-1039.
4. Avetisov E.S., Savitskaya N.F. Some Features of the Ocular Microcirculation in Myopia 1977, pp. 1261-1264.
5. Avila M.P., Weiter J.J., Jalkh A.E., Trempe C.L., Pruett R.C., Schepens C.L. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 1984, 91:1573-1581.
6. Axer-Siegel R., Cotlear D., Priel E., Rosenblatt I., Snir M., Weinberger D. Indocyanine green angiography in high myopia. Ophthalmic Surg. Lasers Imaging 2004, 35:139-145.
7. Axer-Siegel R., Ehrlich R., Weinberger D. Photodynamic therapy of subfoveal choroidal neovascularization in high myopia in a clinical setting: visual outcome in relation to age at treatment. Am. J. Ophthalmol. 2004, 138:602-607.
8. Azab M., Boyer D.S., Bressler N.M. Visudyne in Minimally Classic Choroidal Neovascularization Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch. Ophthalmol. 2005, 123:448-457.
9. Au Eong K.G. Initial experience of macular translocation in Singapore-one year results. Ann. Acad. Med. Singapore 2004, 33:641-648.
10. Baba T., Kubota-Taniai M., Kitahashi M., Okada K., Mitamura Y., Yamamoto S. Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularization. Br. J. Ophthalmol. 2010, 94:864-870.
11. Baba T., Ohno-Matsui K., Yoshida T. Optical coherence tomography of choroidal neovascularization in high myopia. Acta Ophthalmol. 2002, 80:82-87.
12. Bakri S.J., Snyder M.R., Reid J.M., Pulido J.S., Ezzat M.K., Singh R.J. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007, 114:2179-2182.
13. Bandello F., Lanzetta P., Parodi M.B., Roman-Pognuz D., Saviano S., Ravalico G. Photodynamic therapy of subfoveal recurrences after laser photocoagulation of extrafoveal choroidal neovascularization in pathologic myopia. Graefe's Arch. Clin. Exp. Ophthalmol. 2003, 241:567-570.
14. Bennett M.D., Yee W. Pegaptanib for myopic choroidal neovascularization in a young patient. Graefes Arch. Clin. Exp. Ophthalmol. 2007, 245:903-905.
15. Benson M.T., Callear A., Tsaloumas M., Chhina J., Beatty S. Surgical excision of subfoveal neovascular membranes. Eye 1998, 12:768-774.
16. Blair M.P., Apte R.S., Miskala P.H., Bressler S.B., Goldberg M.F., Schachat A.P., Bressler N.M. Retrospective case-series of juxtafoveal choroidal neovascularization treated with photodynamic therapy with verteporfin. Retina 2004, 24:501-506.
17. Bottoni F., Airaghi P., Perego E., Ortolina S., Carlevaro G., Molfetta V.D. Surgical removal of idiopathic, myopic and age-related subfoveal choroidal neovascularization. Graefes Arch. Clin. Exp. Ophthalmol. 1996, 234:S42-S50.
18. Bottoni F., Perego E., Airaghi P. Surgical removal of subfoveal choroidal neovasular membranes in high myopia. Graefes Arch. Clin. Exp. Ophthalmol. 1999, 237:573-582.
19. Bottoni F., Tilanus M. The natural history of juxtafoveal and subfoveal choroidal neovascularization in high myopia. Int. Ophthalmol. 2001, 24:249-255.
20. Brancato R., Menchini U., Pece A., Capoferri C., Avanza P., Radrizzani E. Dye laser photocoagulation of macular subretinal neovascularization in pathological myopia. A randomized study of three different wavelengths. Int. Ophthalmol. 2011, 11:235-238.
21. Brancato R., Pece A., Avanza P., Radrizzani E. Photocoagulation scar expansion after laser therapy for choroidal neovascularization in degenerative myopia. Retina 1990, 10:239-243.
22. Byeon S.H., Kwon O.W., Lee S.C., Kim S.S., Koh H.J. Indocyanine green angiographic features of myopic subfoveal choroidal neovascularization as a prognostic factor after photodynamic therapy. Korean J. Ophthalmol. 2006, 20:18-25.
23. Carneiro A., Falcao M., Pirraco A. Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells. Exp. Eye Res. 2009, 88:522-527.
24. Carnuccio R., Di Rosa M., Guerrasio B. Vasocortin: a novel glucocortecoid-induced anti-inflammatory protein. Br. J. Pharmacol. 1987, 90:443-445.
25. Chan W.-M., Ohji M., Lai T.Y., Liu D.T., Tano Y., Lam D.S.C. Choroidal neovascularization in pathological myopia: an update in management. Br. J. Ophthalmol. 2005, 89:1522-1528.
26. Chan W.M., Lai T.Y., Chan K.P. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia. Retina 2008, 28:1308-1313.
27. Chan W.M., Lai T.Y., Liu D.T., Lam D.S.C. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: 1-year results of a prospective pilot study. Br. J. Ophthalmol. 2009, 93:150-154.
28. Chan W.M., Lai T.Y., Wong A.L., Liu D.T., Lam D.S.C. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularization secondary to pathological myopia: a pilot study. Br. J. Ophthalmol. 2007, 91:174-179.
29. Chan W.M., Lai T.Y., Liu D.T., Lam D.S.C. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-months results of a prospective study. Ophthalmology 2007, 114:2190-2196.
30. Chan W.M., Lam D.S.C., Liu D.T., Wong T.H., Yuen K.S.C. Photodynamic therapy for recurrent choroidal neovascularization after limited macular translocation surgery. Br. J. Ophthalmol. 2003, 87:1188-1189.
31. Chen Y.S., Lin J.Y.S., Tseng S.Y., Yow S.G., Hsu W.J., Tsai S.C. Photodynamic therapy for Taiwanese patients with pathologic myopia: a 2-year follow up. Retina 2007, 27:839-845.
32. Ciulla T.A., Criswell M.H., Danis R.P. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch. Ophthalmol. 2001, 119:399-404.
33. Ciulla T.A., Criswell M.H., Danis R.P. Choroidal neovascular membrane inhibition in a laser treated rat model with intraocular sustained release triamcinolone acetonide microimplants. Br. J. Ophthalmol. 2003, 87:1032-1037.
34. Cohen S.Y., Laroche A., Leguen Y. Etiology of choroidal neovascularization in young patients. Ophthalmology 1996, 103:1241-1244.
35. Cohen S.Y., Bulik A., Dubois L., Quentel G. Photodynamic therapy for juxtafoveal choroidal neovascularization in myopic eyes. Am. J. Ophthalmol. 2003, 136:371-374.
36. Costa R.A., Calucci D., Teixeira L.F., Cardillo J.A., Bonomo P.P. Selective occlusion of subfoveal choroidal neovascularization in pathologic myopia using a new technique of in growth site treatment. Am. J. Ophthalmol. 2003, 135:857-866.
37. Costa R.A., Farah M.E., Cardillo J.A., Belfort R. Photodynamic therapy with indocyanine green for occult subfoveal choroidal neovascularization caused by age-related macular degeneration. Curr. Eye Res. 2001, 23:271-275.
38. Costa R.A., Farah M.E., Freymuller E. Choriocapillaris photodynamic therapy using indocyanine green. Am. J. Ophthalmol. 2001, 132:557-565.
39. Costa R.A., Jorge R., Calucci D. Intravitreal Bevacizumab for Choroidal Neovascularization Caused by AMD (IBeNA Study); Results of a Phase 1 Dose-Escalation Study 2006, pp. 4569-4578.
40. Costa R.A., Williams G.A. Twofold illumination photodynamic therapy scheme for subfoveal choroidal neovascularization in pathologic myopia. Results from a randomized pilot study. Retina 2006, 26:757-764.
41. Curtin B.J. Physiologic vs pathologic myopia: genetics vs environment. Ophthalmology 1979, 86:681-691.
42. Curtin B.J. Ocular findings and complications. The Myopias 1985, 277-347. Harper & Row, Philadelphia. B.J. Curtin (Ed.).
43. Curtin B.J. The Myopias: Basic Science and Clinical Management 1985, Harper and Row, Philadelphia.
44. Curtin B.J. The prevalence of myopia. The Myopias: Basic Science and Clinical Management 1985, 39-59. Harper and Row, Philadelphia. B.J. Curtin (Ed.).
45. Curtin B.J., Karlin D.B. Axial length measurement and fundus changes of the myopic eyes. Am. J. Ophthalmol. 1971, 42-50.
46. de Juan E., Loewenstein A., Bressler N.M., Alexander J. Translocation of the retina for management of subfoveal choroidal neovascularization II: a preliminary report in humans. Am. J. Ophthalmol. 1998, 125:635-646.
47. Degenring R.F., Jonas J.B. Photodynamic therapy in combination with intravitreal triamcinolone for myopic choroidal neovascularization. Acta Ophthalmol. Scand. 2005, 621.
48. Del Priore L.V., Hornbeck R., Jones Z. Surgical removal of the retinal pigment epithelium causes atrophy of the choriocapillaris and outer retina. Invest. Ophthalmol. Vis. Sci. 1995, 35:1142.
49. Delori F.C., Goger D.G., Dorey C.K. Age-related accumulation and spatial distribution of lipofuscin in RPE of normal subjects. Invest. Ophthalmol. Vis. Sci. 2001, 42:1855-1866.
50. Delori F.C., Staurenghi G. In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. Invest. Ophthalmol. Vis. Sci. 1995, 36:718-729.
51. Desmettre T., Maurage C.A., Mordon S. Heat shock protein hyperexpression on chorioretinal layers after transpupillary thermotherapy. Invest. Ophthalmol. Vis. Sci. 2001, 42:2976-2980.
52. Dimitrova G., Tamaki Y., Kato S., Nagahara M. Retrobulbar circulation in myopic patients with or without myopic choroidal neovascularization. Br. J. Ophthalmol. 2002, 86:771-773.
53. Duke-Elder S. Pathological refractive errors. System of Ophthalmology. Ophthalmic Optics and Refraction 1970, 297-373. Mosby, St. Louis.
54. Ergun E., Heinzl H., Stur M. Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia. Am. J. Ophthalmol. 2004, 138:434-438.
55. Essex R.W., Tufail A., Bunce C., Aylward G.W. Two-year results of surgical removal of choroidal neovascular membranes related to non-age-related macular degeneration. Br. J. Ophthalmol. 2007, 91:649-654.
56. Espinosa-Heidmann D.G., Suner I., Hernandez E.P. Age as an independent risk factor for severity of experimental choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2002, 43:1567-1573.
57. Fercher A.F., Hitzenberger C.K., Drexler W., Kamp G., Sattmann H. In vivo optical coherence tomography. Am. J. Ophthalmol. 1993, 116:113-114.
58. Forster R. Ophthalmologische Beitrage 1862, TCF Enslin, pp. 55.
59. Fredrick D.R. Myopia. BMJ 2002, 324:1195-1199.
60. Fried M., Siebert A., Meyer-Schwickerath G., Wessing A. Natural history of Fuchs spot: a long term follow-up study. Doc Ophthalmol. Proc. Ser. 1981, 28:215-221.
61. Fuchs E. Der centrale schwarze Fleck bei Myopie. Z. Augenheilkd 1901, 5:171-178.
62. Fuji G.Y., Humayun M.S., Pieramici D.J. Initial experience of inferior limited macular translocation for subfoveal choroidal neovascularization resulting from causes other than age-related macular degeneration. Am. J. Ophthalmol. 2001, 131:90-100.
63. Fuji G.Y., Humayun M.S., Pieramici D.J. Inferior limited macular translocation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: 1-year visual outcome and recurrence report. Am. J. Ophthalmol. 2002, 134:69-74.
64. Fujikado T., Ohji M., Saito Y., Hayashi A., Tano Y. Visual function after foveal translocation with scleral shortening in patients with myopic neovascular macuolopathy. Am. J. Ophthalmol. 1998, 125:647-656.
65. Fujikado T., Ohji M., Kusaka S., Hayashi A., Kamei M., Okada A.A., Oda K., Tano Y. Visual function after foveal translocation with 360-degree retinotomy and simultaneous torsional muscle surgery in patients with myopic neovascular maculopathy. Am. J. Ophthalmol. 2001, 131:101-110.
66. Fung A.E., Rosenfeld P.J., Reichel E. The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br. J. Ophthalmol. 2006, 90:1344-1349.
67. Gao L.Q., Liu W., Liang Y.B., Zhang F., Wang J.J., Peng Y., Wong T.Y., Wang N.L., Mitchell P., Friedman D.S. Prevalence and characteristics of myopic retinopathy in a rural Chinese adult population: the Handan eye study. Arch. Ophthalmol. 2011, 129:1199-1204.
68. Garcia-Layana A., Salinas-Alaman A., Maldonado M.J., Sainz-Gomez C., Fernandez-Hortelano A. Optical coherence tomography to monitor photodynamic therapy in pathological myopia. Br. J. Ophthalmol. 2006, 90:555-558.
69. Gass J.D.M. Pathogenesis of disciform detachment of the neuroepithelium VI. Disciform detachment secondary to heredodegenerative, neoplastic and traumatic lesions of the choroid. Am. J. Ophthalmol. 1967, 63:689-711.
70. Gass J.D.M. Pathogenesis of disciform detachment of the neuroepithelium. I. General concepts and classification. Am. J. Ophthalmol. 1967, 63:558-573.
71. Gass J.D.M. Stereoscopic Atlas of Macular Diseases: Diagnosis and Treatment 1997, CV Mosby, St. Louis.
72. Gaudreault J., Fei D., Beyer J.C., Ryan A., Rangell L., Shiu V., Damico L.A. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina 2007, 27:1260-1266.
73. Gelisken F., Lafaut B.A., Inhoffen W., Voelker M., Grisanti S., Bartz-Schmidt K.U. Clinicopathological findings of choroidal neovascularization following verteporfin photodynamic therapy. Br. J. Ophthalmol. 2004, 88:207-211.
74. Gelisken F., Inhoffen W., Hermann A., et al. Verteporfin photodynamic therapy for extrafoveal choroidal neovascularization in pathologic myopia. Graefes Arch. Clin. Exp. Ophthalmol. 2004, 242:926-930.
75. Gharbiya M., Allievi F., Mazzeo L., Balacco G. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12 month results. Am. J. Ophthalmol. 2009, 147:84-93.
76. Gharbiya M., Giustolisi R., Allievi F. Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab-A randomized controlled trial. Am. J. Ophthalmol. 2010, 149:458-464.
77. Gibran G.K., Sachdev A., Stappler T., Newsome R., Wong D., Hiscott P. Histological findings of a choroidal neovascular membrane removed at the time of macular translocation in a patient previously treated with intravitreal bevacizumab treatment (Avastin). Br. J. Ophthalmol. 2007, 91:602-604.
78. Glacet-Bernard A., Simon P., Hamelin N., Coscas G., Soubrane G. Translocation of the macula for management of subfoveal choroidal neovascularization: comparison of results in age-related macular degeneration and degenerative myopia. Am. J. Ophthalmol. 2001, 131:78-89.
79. Goh W.S., Lam C.S. Changes in refractive trends and optical components of Hong kong Chinese aged 19-39 years. Ophthalmic Physiol. Opt. 1994, 14:378-382.
80. Grossniklaus H.E., Gass J.D.M. Clinicopathologic correlations of surgically excised type 1and type 2 submacular choroidal neovascular membranes. Am. J. Ophthalmol. 1988, 126:59-69.
81. Grossniklaus H.E., Hutchinson A.K., Capone A. Pathologic findings in pathologic myopia. Retina 1992, 12:127-133.
82. Haimovici R., Kramer M., Miller J.W. Localization of lipoprotein-delivered benzoporphyrin derivative in the rabbit eye. Curr. Eye Res. 1997, 16:83-90.
83. Hamelin N., Glacet-Bernard A., Brindeau C., Mimoun G., Coscas G., Soubrane G. Surgical treatment of subfoveal neovascularization in myopia: macular translocation vs surgical removal. Am. J. Ophthalmol. 2002, 133:530-536.
84. Hampton G.R., Kohen D., Bird A.C. Visual prognosis of disciform degeneration in myopia. Ophthalmology 1983, 90:923-926.
85. Harman A.M., Hoskins R., Beazley L.D. Experimental eye enlargement in mature animals changes the retinal pigment epithelium. Vis. Neurosci. 1999, 16:619-628.
86. Hayashi K., Ohno-Matsui K., Shimada N., Moriyama M., Hara W., Yoshida T., Tokoro T., Mochizuki M. Intravitreal bevacizumab on myopic choroidal neovascularization that was refractory to or had recurred after photodynamic therapy. Graefes Arch. Clin. Exp. Ophthalmol. 2009, 247:609-618.
87. Hayashi K., Ohno-Matsui K., Shimada N., Moriyama M., Hayashi W., Wang J.J., Yoshida T., Tokoro T., Mochizuki M. Long-term results of photodynamic therapy for choroidal neovascularization in Japanese patients with pathologic myopia. Am. J. Ophthalmol. 2011, 151:137-147.
88. Hayashi K., Ohno-Matsui K., Teramukai S., Shimada N., Moriyama M., Hara W., Yoshida T., Tokoro T., Mochizuki M. Photodynamic therapy with verteporfin for choroidal neovascularization of pathologic myopia in Japenese patients: comparison with nontreated controls. Am. J. Ophthalmol. 2008, 145:518-526.
89. Hayashi K., Ohno-Matsui K., Teramukai S., Shimada N., Moriyama M., Hayashi W., Yoshida T., Tokoro T., Mochizuki M. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy. Am. J. Ophthalmol. 2009, 148:396-408.
90. Hayashi K., Ohno-Matsui K., Yoshida T., Kobayashi K., Kojima A., Shimada N., Yasuzumi K., Futagami S., Tokoro T., Mochizuki M. Characteristics of patients with a favorable natural course of myopic choroidal neovascularization. Graefes Arch. Clin. Exp. Ophthalmol. 2005, 243:13-19.
91. Hayashi K., Shimada N., Moriyama M., Hayashi W., Tokoro T., Ohno-Matsui K. Two year outcome of intravitreal bevacizumab for choroidal neovascularization in Japanese patients with pathological myopia. Retina 2011.
92. Hee M.R., Baumal C.R., Puliafito C.A. Optical coherence tomography of age-related macular degeneration and choroidal neovascularization. Ophthalmology 1996, 103:1260-1270.
93. Hernandez-Rojas M.L., Quiroz-Mercado H., Dalma-Weiszhausz J., Fromow-Guerra J., Amaya-Espinosa A., Solis-Vivanco A., Reyna-Castelan E., Abraham-Marin M., Martinez-castellanos M.A., Aiello L.P. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 2007, 27:707-712.
94. Hotchkiss M.L., Fine S.L. Pathological myopia and choroidal neovascularization. Am. J. Ophthalmol. 1981, 91:177-183.
95. Husain D., Miller J.W., Michaud N., Connolly E., Flotte T.J., Gragoudas E.S. Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization. Arch. Ophthalmol. 1996, 114:978-985.
96. Hussain N., Khanna R., Das T. Two year follow-up outcome of verteprofin therapy for subfoveal choroidal neovascualrization in pathologic myopia in Indian eyes. Indian J. Ophthalmol. 2008, 56:465-468.
97. Hussain N., Das T., Vashist U., Sumashri K. Verteporfin therapy for myopic choroidal neovascularization in Indian eyes (one year results). Indian J. Ophthalmol. 2004, 52:227-231.
98. Ichibe M., Imai K., Ohta M., Hasebe H., Yoshizawa T., Abe H. Foveal translocation with scleral imbrication in patients with myopic neovascular maculopathy. Am. J. Ophthalmol. 2001, 132:164-171.
99. Ignoffo R.J. Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor. Am. J. Health Syst. Pharm. 2004, 61:21-26.
100. Ikuno Y., Nagai Y., Matsuda S., Arisawa A., Sho K., Oshita T., Takahashi K., Uchihori Y., Gomi F. Two-year visual results for older asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization. Am. J. Ophthalmol. 2010, 149:140-146.
101. Ikuno Y., Sayanagi K., Soga K. Lacquer crack formation and choroidal neovascularization in pathological myopia. Retina 2008, 28(8):1124-1131.
102. Ikuno Y., Sayanagi K., Soga K., Sawa M., Tsujikawa M., Gomi F., Tano Y. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am. J. Ophthalmol. 2009, 94-100.
103. Ishibashi T., Miki K., Sorgente N. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in subhuman primate. Arch. Ophthalmol. 1985, 103:708-711.
104. Iwase A., Araie M., Tomidokoro A. Prevalence and causes of low vision and blindness in a Japanese adult population. Ophthalmology 2010, 117:1595-1611.
105. Jampol L.M., Scott L. Treatment of juxtafoveal and extrafoveal choroidal neovascularization in the era of photodynamic therapy with verteporfin. Am. J. Ophthalmol. 2002, 134:99-101.
106. Jo Y., Ikuno Y., Nishida K. Retinoschisis: a predictive factor in vitrectomy for macular holes without retinal detachment in highly myopic eyes. Br. J. Ophthalmol. 2012, 96:197-200.
107. Johnson D.A., Yannuzzi L.A., Shakin J.L., Lightman D.A. Lacquer cracks following laser treatment of choroidal neovascularization in pathologic myopia. Retina 1988, 18:118-124.
108. Jonas J.B., Kreissig I., Degenring R.F. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br. J. Ophthalmol. 2003, 87:24-27.
109. Kayazawa F., Tamura S., Tsuji T., Matsuda T., Kuwayama W., Machida T. The influence of aging on vitreous fluorophotometry. J. Jpn. Ophthalmol. Soc. 1983, 87:380-383.
110. Keane P.A., Liakopoulos S., Chang K.T., Heussen F.M., Ongchin S.C., Walsh A.C., Sadda S.R. Comparison of the optical coherence tomographic features of choroidal neovascular membranes in pathological myopia versus age-related macular degeneration, using quantitative subanalysis. Br. J. Ophthalmol. 2008, 92:1081-1085.
111. Kitaya N., Ishiko S., Abiko T., Mori F., Kagokawa H., Kojima M., Saito K., Yoshida A. Changes in blood retinal barrier permeability in form deprivation myopia in tree shrews. Vis. Res. 2000, 40:2369-2377.
112. Klein R.M., Green S. The development of lacquer cracks in pathologic myopia. Am. J. Ophthalmol. 1988, 106:282-285.
113. Klettner A., Roider J. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Invest. Ophthalmol. Vis. Sci. 2008, 49:4523-4527.
114. Kobayashi H., Kobayashi K. Radiotherapy for subfoveal neovascularization associated with pathological myopia: a pilot study. Br. J. Ophthalmol. 2000, 84:761-766.
115. Kobayashi K., Mandai M., Suzuma I., Kobayashi H., Okinami S. Expression of estrogen receptor in the choroidal neovascular membranes in highly myopic eyes. Retina 2002, 22:418-422.
116. Kojima A., Ohno-Matsui K., Futagami S., Noriaki S., Tokoro T., Mochizuki M. Trans-Tenon's retrobulbar triamcinolone infusion for myopic choroidal neovascularization. Acta Ophthalmol. Scand. 2006, 84:749-754.
117. Kojima A., Ohno-Matsui K., Teramukai S., Yoshida T., Ishihara Y., Kobayashi K., Shimada N., Yasuzumi K., Futagami S., Tokoro T., Mochizuki M. Factors associated with the development of chorioretinal atrophy around choroidal neovascularization. Graefes Arch. Clin. Exp. Ophthalmol. 2004, 242:114-119.
118. ®) for the treatment of myopic choroidal neovascularization. Graefes Arch. Clin. Exp. Ophthalmol. 2009, 247:311-318.
119. Korte G.E., Reppucci V., Henkind P. RPE destruction causes choriocapillaris atrophy. Invest. Ophthalmol. Vis. Sci. 1984, 25:1135-1145.
120. Krebs I., Binder S., Stolba U., Glittenberg C., Brannath W., Goll A. Choroidal neovascularization in pathologic myopia: three-year results after photodynamic therapy. Am. J. Ophthalmol. 2005, 140:416-425.
121. Kumaran N., Sim D.A., Tufail A. Long-term remission of myopic choroidal neovascular membrane after treatment with ranibizumab; a case-report. J. Med. Case Rep. 2009, 3:84.
122. Kwak N., Okamoto N., Wood J.M. VEGF is major stimulator in model of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2000, 41:3158-3164.
123. Ladas I.D., Moschos M.M., Rouvas A.A., Karagiannis D.A., Kokolakis S. Lacquer crack formation after photodynamic therapy. Eur. J. Ophthalmol. 2003, 13:729-733.
124. Lai T.Y.Y., Chan W.M., Liu D.T.L., Lam D.S.C. Intravitreal ranibizumab for primary treatment of choroidal neovascularization secondary to pathologic myopia. Retina 2009, 29:750-756.
125. Lalloum F., Souied E.H., Bastuji-Garin S., Puche N., Querques G., Glacet-Bernard A., Coscas G., Soubrane G., Leveziel N. Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia. Retina 2010, 30:399-406.
126. Lam D.S.C., Chan W.-M., Liu D.T., Fan D.S.P., Lai W.W., Chong K.K.L. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization of pathologic myopia in chinese eyes: a prospective series of 1 and 2 year follow up. Br. J. Ophthalmol. 2004, 88:1315-1319.
127. Lam D.S.C., Liu D.T., Fan D.S.P., Lai W.W., So S.F., Chan W.-M. Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization secondary to pathologic myopia - 1 year results of a prospective series. Eye 2005, 19:834-840.
128. Lanzetta P., Parodi M.B., Ambesi-Impiombato M., Ravalico G., Bandello F. Early neovascular bridging after photodynamic therapy of myopic choroidal neovascularization. Graefes Arch. Clin. Exp. Ophthalmol. 2004, 242:840-844.
129. Laud K., Spaide R.F., Freund K.B., Slakter J., Klancnik J.M. Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 2006, 26:960-962.
130. Lewis H., Kaiser P.K., Lewis S. Macular translocation for subfoveal choroidal neovascularization in age-related macular degeneration: a prospective study. Am. J. Ophthalmol. 1999, 129:135-146.
131. Li Y.J., Goh L., Khor C.C., Fan Q., Yu M., Han S., Sim X., Ong R.T., Wong T.Y., Vithana E.N., Yap E., Nakanishi H., Matsuda F., Ohno-Matsui K., Yoshimura N., Seielstad M., Tai E.S., Young T.L., Saw S.M. Genome-wide association studies reveal genetic variants in CTNND2 for high myopia in Singapore Chinese. Ophthalmology 2011, 118:368-375.
132. Lim L.S., Cheung C.M., Mitchell P., Wong T.Y. Emerging evidence concerning systemic safety of anti-VEGF agents-should ophthalmologists be concerned?. Am. J. Ophthalmol. 2011, 152:329-331.
133. Lin L.L.K., Shih Y.F., Tsai C.B. Epidemiologic study of ocular refraction among school-children in Taiwan in 1995. Optom. Vis. Sci. 1999, 76:275-281.
134. Lipski A., Bornfeld N., Jurklies B. Photodynamic therapy with verteporfin in pediatric and young adult patients: long-term treatment results of choroidal neovascularizations. Br. J. Ophthalmol. 2008, 92:655-660.
135. Lloyd R.I. Clinical studies of the myopic macula. Trans. Am. Ophthalmol. Soc. 1953, 51:273-284.
136. Loh B.K., Lee S.Y., Cheng J., Yeo I., Wong D., Ang C.L. Intravitreal bevacizumab for the treatment of myopic choroidal neovascularization in an Asian population. Ann. Acad. Med. Singapore 2010, 39:493-494.
137. Maar N., Ergun E., Luksch A., Stur M. Treatment frequency and visual outcome in subfoveal choroidal neovascularization related to pathologic myopia treated with photodynamic therapy. Graefes Arch. Clin. Exp. Ophthalmol. 2006, 244:1262-1266.
138. Machemer R., Steinhorst U.H. Retinal separation, retinotomy, and macular relocation: II. A surgical approach for age-related macular degeneration?. Graefes Arch. Clin. Exp. Ophthalmol. 1993, 231:635-641.
139. Macular Photocoagulation Study Group Laser photocoagulation of subfoveal neovascular lesion in age-related macular degeneration: results of a randomized clinical trial. Arch. Ophthalmol. 1991, 109:1220-1231.
140. Macular Photocoagulation Study Group Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration: updated findings from two clinical trials. Arch. Ophthalmol. 1993, 111:1200-1209.
141. Manzano R.P., Peyman G.A., Khan P. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006, 26:257-261.
142. Marticorena J., Gomez-Ulla F., Fernandez M., Pazos B., Rodriguez-Cid M.J., Sanchez-Salorio M. Combined photodynamic therapy and intravitreal triamcinolone acetonide for the treatment of myopic subfoveal choroidal neovascularization. Am. J. Ophthalmol. 2006, 142:335-337.
143. Mateo C., Moreno J., Rosales G., Lechuga M., Castillo R., Vaz F., Corcostegui B. Two-year results of macular translocation with scleral infolding in myopic choroidal neovascularization. Semin. Ophthalmol. 2004, 19:29-42.
144. Matusumaru H., Hirai H. Prevalence of myopia and refractive changes in students from 3 to 17 years of age. Surv. Ophthalmol. 1999, 44:109-115.
145. Miller D.G., Singerman L.J. Natural history of choroidal neovascularization in high myopia. Curr. Opin. Opthalmol 2001, 12:222-224.
146. Miller H., Miller B., Ishibashi T., Ryan S.J. Pathogenesis of laser-induced choroidal subretinal neovascularization. Invest. Ophthalmol. Vis. Sci. 1990, 31:899-908.
147. Miller H., Miller B., Ryan S.J. The role of retinal pigment epithelium in the involution of subretinal neovascularization. Invest. Ophthalmol. Vis. Sci. 1986, 27:1644-1652.
148. Miller J.W., Schmidt-Erfurth U., Sickenberg M. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch. Ophthalmol. 1999, 117:1161-1173.
149. Ming Y., Algvere P.V., Odergren A. Subthreshold transpupillary thermotherapy reduces experimental choroidal neovascularization in the mouse without collateral damage to the neural retina. Invest. Ophthalmol. Vis. Sci. 2004, 45:1969-1974.
150. Mones J.M., Amselem L., Serrano A., Garcia M., Hijano M. Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results. Eye 2009, 23:1275-1281.
151. Montero J.A., Ruiz-Moreno J.M. Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularization. Br. J. Ophthalmol. 2003, 87:173-176.
152. Montero J.A., Ruiz-Moreno J.M. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularization secondary to pathological myopia: a pilot study. Br. J. Ophthalmol. 2007, 91:133.
153. Montero J.A., Ruiz-Moreno J.M. Treatment of choroidal neovascularization in high myopia. Curr. Drug Targets 2010, 11:630-644.
154. Morgan C.M., Schatz H. Atrophic creep of the retinal pigment epithelium after focal macular photocoagulation. Ophthalmology 1989, 96:96-103.
155. Nagaoka N., Shimada N., Hayashi W., Hayashi K., Moriyama M., Yoshida T., Tokoro T., Ohno-Matsui K. Characteristics of periconus choroidal neovascularization in pathologic myopia. Am. J. Ophthalmol. 2011, 152:420-427.
156. Nakanishi H., Tsujikawa A., Yodoi Y., Ojima Y., Otani A., Tamura H., Yamashiro K., Ooto S., Yoshimura N. Prognostic factors for visual outcomes 2 years after intravitreal bevacizumab for myopic choroidal neovascularization. Eye 2011, 25:375-381.
157. Narang P.S., Kaur S., Kumar R. Serum zinc and copper levels in myopia, corneal ulcer and diabetic retinopathy. Trace Elem. Electrolytes 2001, 18:92-100.
158. Nguyen Q.D., Shah S., Tatlipinar S., Do D.V., Anden E.V., Camppochiaro P.A. Bevacizumab suppresses choroidal neovascularization caused by pathological myopia. Br. J. Ophthalmol. 2005, 89:1-3.
159. Nguyen Q.D., Shah S., Hafiz G., Do D.V., Haller J.A., Pili R., Zimmer-Galler I.E., Janjua K., Symons R.A.C., Campochiaro P.A. Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degeneration. Am. J. Ophthalmol. 2008, 145:257-266.
160. Ninomiya Y., Lewis J.M., Hasegawa T., Tano Y. Retinotomy and foveal translocation for surgical management of subfoveal choroidal neovascular membranes. Am. J. Ophthalmol. 1996, 122:613-621.
161. Nishijima K., Ng Y.S., Zhong L., Bradley J., Schubert W., Jo N. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptative response to ischemic injury. Am. J. Pathol. 2007, 171:53-67.
162. Noble K.G., Carr R.E. Pathologic myopia. Ophthalmology 1982, 89:1099-1100.
163. Noske U.M., Schmidt-Erfurth U., Meyer C. Lipid metabolism in retinal pigment epithelium. Possible significance of lipoprotein receptors. Ophthalmologe 1998, 95:814-819.
164. Oh H., Takagi H., Takagi C. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest. Ophthalmol. Vis. Sci. 1999, 40:1891-1898.
165. Ohji M., Fujikado T., Saito Y., Hosohata J., Hayashi A., Tano Y. Foveal translocation: a comparison of two techniques. Semin. Ophthalmol. 1988, 13:52-61.
166. Ohno-Matsui K., Moriyama M., Hayashi K., Mochizuki M. Choroidal vein and artery occlusion following photodynamic therapy in eyes with pathologic myopia. Graefes Arch. Clin. Exp. Ophthalmol. 2006, 244:1363-1366.
167. Ohno-Matsui K., Yoshida T., Futagami S. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularization in pathologic myopia. Br. J. Ophthalmol. 2003, 87:570-573.
168. Okabe S., Matsuo N., Okamoto S., Kataoka H. Electron microscopic studies on retinochoroidal atrophy in the human eye. Acta Med. Okayama 1982, 36:11-21.
169. Olsen T.W. Treatment of exudative age-related macular degeneration: many factors to consider. Am. J. Ophthalmol. 2007, 144:281-283.
170. Oshima Y., Harino S., Tano Y. Scanning laser ophthalmoscope microperimetric assessment in patients with successful laser treatment for juxtafoveal choroidal neovasccularization. Retina 1998, 18:109-117.
171. Ozdek S., Hondur A., Gurelik G., Hasanreisoglu B. Transpupillary thermotherapy for myopic choroidal neovascularization: 1-year follow-up. Int. Ophthalmol. 2005, 26:127-133.
172. Pan C.W., Wong T.Y., Lavanya R., Wu R.Y., Zheng Y.F., Lin X.Y., Mitchell P., Aung T., Saw S.M. Prevalence and risk factors for refractive errors in Indians: the Singapore Indian Eye Study (SINDI). Invest. Ophthalmol. Vis. Sci. 2011, 52:3166-3173.
173. Parodi M.B., Da Pozzo S., Ravalico G. Angiographic features after photodynamic therapy for choroidal neovascularization in age-related macular degeneration and pathological myopia. Br. J. Ophthalmol. 2003, 87:177-183.
174. Parodi M.B., Iacono P., Ravalico G. Fundus autofluorescence in subfoveal choroidal neovascularization secondary to pathological myopia. Br. J. Ophthalmol. 2009, 93:771-774.
175. Parodi M.B., Pozzo S.D., Ravalico G. Retinal pigment epithelium changes after photodynamic therapy for choroidal neovascularization in pathological myopia. Acta Ophthalmol. Scand. 2007, 85:50-54.
176. Pece A., Brancato R., Avanza P., Camesasca F., Galli L. Laser photocoagulation of choroidal neovascularization in pathologic myopia: long-term results. Int. Ophthalmol. 1995, 18:339-344.
177. Pece A., Isola V., Vadala M., Matranga D. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to pathologic myopia. Long-term study. Retina 2006, 26:746-751.
178. Pece A., Vadala M., Isola V., Matranga D. Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization in pathologic myopia. A long-term follow-up study. Am. J. Ophthalmol. 2007, 143:449-454.
179. Penas S.C., Carneiro A., Martinho R., Rosas V., Countinho M., Falcao-Reis F. Optical Coherence Tomography in Myopic Choroidal Neovascularization Treated with Photodynamic Therapy. Invest. Ophthalmol. Vis. Sci. E-Abstract 3167 2004.
180. Peters S., Heiduschka P., Juliens S. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am. J. Ophthalmol. 2007, 143:995-1002.
181. Postelmans L., Pasteels B., Coquelet P., El Ouardighi H., Verougstraete C., Schmidt-Erfurth U. Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females. Am. J. Ophthalmol. 2004, 138:803-808.
182. Potter M.J., Szabo S.M., Ho T. Combined photodynamic therapy and intravitreal triamcinolone for the treatment of myopic choroidal neovascularization in a 13-year-old girl. Graefes Arch. Clin. Exp. Ophthalmol. 2006, 244:639-641.
183. Proia A., Hirakata A., McInnes J. The effect of angiostatic steroids and B-cyclodextrin tetradecasulfate on corneal neovascularization in the rat. Exp. Eye Res. 1993, 57:693-698.
184. Pruett R.C., Weiter J.J., Goldstein R.B. Myopic cracks, angioid streaks, and traumatic tears in Bruch's membrane. Am. J. Ophthalmol. 1987, 103:537-543.
185. Puri R.N., Thakur V., Nema H.V. Role of zinc (Yashad Bhasma) in arrest of myopia. Indian J. Ophthalmol. 1983, 31:816-822.
186. Quaranta M., Arnold J., Coscas G. Indocyanine Green Angiographic Features of Pathologic Myopia 1996, Am. J. Ophthalmol. 122, 663-671.
187. Ramrattan R.S., van der Schaft T.L., Mooy C.M. Morphometric analysis of Bruch's membrane, the choriocapillaris, and the choroid in ageing. Invest. Ophthalmol. Vis. Sci. 1994, 35:2857-2864.
188. Reche-Frutos J., Calvo-Gonzalez C., Donate-Lopez J., Garcia-Feijoo J., Wasfy M., Saenz-Frances F., Fernandez-Perez C., Garcia-Sanchez J. Photodynamic therapy in non-subfoveal choroidal neovascularization secondary to pathological myopia: 1-year outcome. Br. J. Ophthalmol. 2007, 91:1722-1723.
189. Reichel E., Berrocal A.M., Ip M. Transpupillary thermotherapy of occult subfoveal choroidal neovascularization in patients with age-related macular degeneration. Ophthalmology 1999, 106:1908-1914.
190. Rensch F., Spandau U.H.M., Schlichtenbrede F., von Baltz S., Libondi T., Jonas J.B., Vossmerbaeumer U. Intravitreal bevacizumab for myopic choroidal neovascularization. Ophthalmic Surg. Lasers Imaging 2008, 39:182-185.
191. Rubin G.S., Munoz B., Bandeen-Roche K. Monoocular versus binocular visual acuity as measures of vision impairment and predictors of visual disability. Invest. Ophthalmol. Vis. Sci. 2000, 41:3327-3334.
192. Ruiz-Moreno J.M., de la Vega C. Surgical removal of subfoveal choroidal neovascularization in highly myopic eyes. Br. J. Ophthalmol. 2001, 85:1041-1043.
193. Ruiz-Moreno J.M., Amat P., Montero J.A., Lugo F. Photodynamic therapy to treat choroidal neovascularization in highly myopic patients: 4 years' outcome. Br. J. Ophthalmol. 2008, 92:792-794.
194. Ruiz-Moreno J.M., Montero J.A. Subretinal fibrosis after photodynamic therapy in subfoveal choroidal neovascularization in highy myopic eyes. Br. J. Ophthalmol. 2003, 87:856-859.
195. Ruiz-Moreno J.M., Montero J.A., Arias L., Araiz J., Gomez-Ulla F., Silva R., Pinero D.P. Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization. Retina 2010, 30:1609-1615.
196. Ruiz-Moreno J.M., Montero J.A., Gomez-Ulla F. Photodynamic therapy may worsen the prognosis of highly myopic choroidal neovascularization treated by intravitreal bevacizumab. Br. J. Ophthalmol. 2009, 93:1693-1694.
197. Ruiz-Moreno J.M., Montero J.A., Gomez-Ulla F., Ares S. Intravitreal bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: 1 year outcome. Br. J. Ophthalmol. 2009, 93:448-451.
198. Ruiz-Moreno J.M., Gomez-Ulla F., Montero J.A., Ares S., Lopez-Lopez F., Rodriguez M., Fernandez M. Intravitreal bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results. Eye 2009, 23:334-338.
199. Sakaguchi H., Ikuno Y., Gomi F., Kamei M., Sawa M., Tsujikawa M., Oshima Y., Kusaka S., Tano Y. Intravitreal injection of bevacizumab for choroidal neovascularization associated with pathologic myopia. Br. J. Ophthalmol. 2007, 91:161-165.
200. Saperstein D.A., Rosenfeld P.J., Bressler N.M., Rosa R.H., Sickenberg M., Sternberg P. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one year results of an uncontrolled, prospective case series. Ophthalmology 2002, 109:1499-1505.
201. Saw S.M., Chan Y.H., Wong W.L., Shankar A., Sandar M., Aung T., Tan D.T., Mitchell P., Wong T.Y. Prevalence and risk factors for refractive errors in the Singapore Malay Eye Survey. Ophthalmology 2008, 115:1713-1719.
202. Saw S.M., Wong T.Y. Is it possible to slow the progression of myopia?. Ann. Acad. Med. Singapore 2004, 33:4-6.
203. Sawa M., Gomi F., Tsujikawa M., Ikuno Y., Sakaguchi H., Sayanagi K., Tano Y. Abnormal fundus autofluorescence patterns in myopic choroidal neovascularization. Br. J. Ophthalmol. 2008, 92:1236-1240.
204. Sayanagi K., Ikuno Y., Soga K., Wakabayashi T., Tano Y. Marginal crack after intravitreal bevacizumab for myopic choroidal neovascularization. Acta Ophthalmol. (Copenh) 2008, 85:50-54.
205. Schmidt-Erfurth U., Schlotzer-Schrehard U., Cursiefen C., Michels S., Beckendorf A., Naumann G.O. Influence of photodynamic therapy on expresssion of vascular endothelial growth factor (VEGF), VEGF receptor 3 and pigment epithelium-derived factor. Invest. Ophthalmol. Vis. Sci. 2003, 44:4473-4480.
206. Schnurrbusch U.E.K., Jochmann C., Wiedmann P., Wolf S. Quantitative assessment of the long-term effect of photodynamic therapy in patients with pathologic myopia. Graefe's Arch. Clin. Exp. Ophthalmol. 2005, 243:829-833.
207. Scupola A., Tiberti A.C., Sasso P., Savastano M.C., Mastrocola A., Marangoni D., Minnella A.M., Falsini B., Balestrazzi E. Macular functional changes evaluated with MP-1 microperimetry after intravitreal bevacizumab for subfoveal myopic choroidal neovascularization. Retina 2010, 30:739-747.
208. Secretan M., Kuhn D., Soubrane G., Coscas G. Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur. J. Ophthalmol. 1997, 7:307-316.
209. Seet B., Wong T.Y., Tan D.T.H., Saw S.M., Balakrishnan V., Lee L.K.H., Lim A.S.M. Myopia in Singapore: taking a public health approach. Br. J. Ophthalmol. 2001, 85:521-526.
210. Seko Y., Fujikura H. Induction of vascular endothelial growth factor after application of mechanical stress to retinal pigment epithelium of the rat in vitro. Invest. Ophthalmol. Vis. Sci. 1999, 40:3287-3291.
211. Shahar J., Avery R.L., Heilweil G. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006, 26:262-269.
212. Shapiro M., Chandra S.R. Evolution of lacquer cracks in high myopia. Ann. Ophthalmol. 1985, 17:231-235.
213. Shima C., Sakaguchi H., Gomi F. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol. 2008, 86:372-376.
214. Shimada N., Ohno-Matsui K., Hayashi K., Yoshida T., Tokoro T., Mochizuki M. Macular detachment after successful intravitreal bevacizumab for myopic choroidal neovascularization. Jpn. J. Clin. Ophthalmol. 2011, 55:378-382.
215. Shimada N., Ohno-Matsui K., Yoshida T., Futagami S., Tokoro T., Mochizuki M. Development of macular hole and macular retinoschisis in eyes with myopic choroidal neovascularization. Am. J. Ophthalmol. 2008, 145:155-161.
216. Shuler M.F., Borrillo J.L., Ho A.C. Photodynamic therapy update. Curr. Opin. Opthalmol 2001, 12:202-206.
217. Sickenberg M., Schmidt-Erfurth U., Miller J.W., Pournaras C.J., Zografos L. A preliminary study of photodynamic therapy with verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angiod streaks, and idiopathic causes. Arch. Ophthalmol. 2000, 117:327-336.
218. Silva R.M., Ruiz-Moreno J.M., Nascimento J., Carneiro A., Rosa P., Barbosa A., Carvalheira F., Abreu F.J.R., Cunha-Vaz J.G. Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization. Retina 2008, 28:1117-1123.
219. Silva R.M., Ruiz-Moreno J.M., Rosa P., Carneiro A., Nascimento J., Rito L.F., Cachulo L.M., Carvalheira F., Murta J.N. Intravitreal ranibizumab for myopic choroidal neovascularization. 12-month results. Retina 2010, 30:407-412.
220. Soubrane G. Choroidal neovascularization in pathologic myopia: recent developments in diagnosis and treatment. Surv. Ophthalmol. 2008, 53:121-138.
221. Spaide R.F. Age-related choroidal atrophy. Am. J. Ophthalmol. 2009, 147:801-810.
222. Srivastava S.K., Paul S. Retinal pigment epithelial tear weeks following photodynamic therapy with verteporfin for choroidal neovascularization secondary to pathologic myopia. Retina 2002, 22:669-671.
223. Stafford W.R. Degeneration and atrophy of choroid. Clinical Ophthalmology 1982, 1-13. Harper & Row, Hagerstown. T.D. Duane (Ed.).
224. Steidl S.M., Pruett R.C. Macular complications associated with posterior staphylomas. Am. J. Ophthalmol. 1997, 123:181-187.
225. Steinbrook R. The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration. N. Engl. J. Med. 2006, 355:1409-1412.
226. Tabandeh H., Flynn H.W., Scott I.U. Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularization. Ophthalmology 1999, 106:2063-2067.
227. Tano Y. Pathologic myopia: where are we now?. Am. J. Ophthalmol. 2002, 134:645-660.
228. Tatar O., Adam A., Shinoda K. Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am. J. Ophthalmol. 2006, 142:95-104.
229. Tewari A., Dhalla M.S., Apte R.S. Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia. Retina 2006, 26:1093-1094.
230. Thomas M.A., Dickinson J.D., Melberg N.S., Ibanez H.E., Dhaliwal R.S. Visual results after surgical removal of subfoveal choroidal neovascular membranes. Ophthalmology 1994, 101:1384-1396.
231. Tong J.P., Lam D.S.C., Chan W.M., Choy K.W., Chan K.P., Pang C.P. Effects of triamcinolone on the expression of VEGF and PEDF in human retinal pigment epithelial and human umblical vein endothelial cells. Mol. Vis. 2006, 12:1490-1495.
232. Truong A., Wong T.Y., Khachigian L.M. Emerging therapeutic approaches in the management of retinal angiogenesis and edema. J. Mol. Med. 2011, 89:343-361.
233. Tsujikawa M., Tsujikawa K., Lewis J.M., Tano Y. Change in retinal sensitivity due to excision of choroidal neovascularization and its influence on visual acuity outcome. Retina 1999, 19:135-140.
234. Uemura A., Thomas M.A. Subretinal surgery for choroidal neovascularization in patients with high myopia. Arch. Ophthalmol. 2000, 118:344-350.
235. Vadala M., Pece A., Cipolla S., Monteleone C., Fasolino G., Casuccio A., Cillino S. Is ranibizumab effective in stopping the loss of vision for choroidal neovascularization in pathologic myopia? A long-term follow-up study. Br. J. Ophthalmol. 2010, 10:1136.
236. Varano M., Tedeschi M., Oddone F., Perillo L., Coppe A.M., Parravano M. Microperimetric retinal changes in myopic choroidal neovascularization treated with intravitreal ranibizumab. Retina 2010, 30:413-417.
237. Verteporfin in Photodynamic Therapy (VIP) Study Group Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with Verteporfin, 1-year results of a randomized clinical trial-VIP Report No 1. Ophthalmology 2001, 108:841-852.
238. Verteporfin in Photodynamic Therapy (VIP) Study Group Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia. 2 year results of a randomized clinical trial - VIP Report No 3. Ophthalmology 2003, 110:667-673.
239. Verteporfin Roundtable 2000 and 2001 Participants, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Principal Investigators Verteporfin, In Photodynamic Therapy (VIP) Study Group Principal Investigators Guidelines for using verteporfin (Visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 2002, 22:6-18.
240. Virgili G., Menchini F. Laser Photocoagulation for Choroidal Neovascularization in Pathologic Myopia (Review), Cochrane Database of Systematic Reviews 2005, Issue 4 2009.
241. Virgili G., Varano M., Giacomelli G. Photodynamic therapy for nonsubfoveal choroidal neovascularization in 100 eyes with pathologic myopia. Am. J. Ophthalmol. 2007, 143:77-82.
242. Vongphanit R., Mitchell P., Wang J.J. Prevalence and progression of myopic retinopathy in an older population. Ophthalmology 2002, 109:704-711.
243. Wakabayashi T., Ikuno Y. Choroidal filling delay in choroidal neovascularization due to pathological myopia. Br. J. Ophthalmol. 2010, 94:611-615.
244. Wakabayashi T., Ikuno Y., Gomi F. Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathological myopia. Retina 2011, X:1-7.
245. Wang Y., Friedrichs U., Eichler W. Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells. Graefes Arch. Clin. Exp. Ophthalmol. 2002, 240:42-48.
246. Weiss A.H. Unilateral high myopia: optical components, associated factors, and visual outcome. Br. J. Ophthalmol. 2003, 87:1025-1031.
247. Wickremasinghe S.S., Michalova K., Gilhotra J., Guymer R.H., Harper C.A., Wong T.Y., Quershi S. Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 2008, 115:1911-1915.
248. Wong T.Y. Age-related macular degeneration: why should stroke physicians care?. Stroke 2010, 41:575-576.
249. Wong T.Y., Foster P.J., Hee J., Ng T.P., Tielsch J.M., Chew S.J. Prevalence and risk factors for refractive errors in adult Chinese in Singapore. Invest. Ophthalmol. Vis. Sci. 2000, 41:2486-2494.
250. Wong T.Y., Foster P.J., Ng T.P., Tielsch J.M., Johnson G.J., Seah S.K.L. Variations in ocular biometry in an adult chinese population in Singapore: the Tanjong Pagar survey. Invest. Ophthalmol. Vis. Sci. 2001, 42:73-80.
251. Wu P.C., Chen Y.J. Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1 year follow-up. Eye 2009, 1-4.
252. Wu P.C., Chen Y.J., Chen C.H. Subthreshold transpupillary thermotherapy in Chinese patients with myopic choroidal neovascularization: one- and two-year follow up. Clin. Exp. Ophthalmol. 2008, 36:443-448.
253. Xu H., Huang K., Gao Q. A study on the prevention and treatment of myopia with nacre on chicks. Pharmacol. Res. 2001, 44:2-6.
254. Xu H., Huang K., Gao Q. Prevention of axial elongation in myopia by the trace element zinc. Biol. Trace Elem. Res. 2001, 79:39-47.
255. Xu L., Wang Y., Lai Y. Causes of blindness and visual impairment in urban and rural areas in Beijing: the Beijing Eye Study. Ophthalmology 2006, 113:1134.
256. Yamada Y., Miyamura N., Suzuma K., Kitaoka T. Long-term follow-up of macular translocation for choroidal neovasularization. Am. J. Ophthalmol. 2010, 149:453-457.
257. Yamamoto I., Rogers A.H., Reichel E., Yates P.A., Duker J.S. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularization secondary to pathological myopia. Br. J. Ophthalmol. 2007, 91:157-160.
258. Yodoi Y., Tsujikawa A., Nakanishi H., Otani A., Tamura H., Ojima Y., Hayashi H., Yoshimura N. Central retinal sensitivity after intravitreal injection of bevacizumab for myopic choroidal neovascularization. Am. J. Ophthalmol. 2009, 147:816-824.
259. Yoganathan P., Fastenberg D.M., Ferrone P.J. Intravitreal bevacizumab 2.5 versus 1.25 mg in exudative age-related macular degeneration. Safety and Efficacy ARVO E abstract 166. 2007.
260. Yoon J.U., Byun Y.J., Koh H.J. Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization. Retina 2010, 30:418-424.
261. Yoshida A., Ishiko S., Kojima M. Inward and outward permeability of the blood-retinal barrier in experimental myopia. Graefes Arch. Clin. Exp. Ophthalmol. 1996, 234:S239-S242.
262. Yoshida A., Murakami K., Kojima M. Investigation of the vitreo-retino-ciliary barrier by vitreous fluorophotometry. Alteration of the inward permeability of the blood-retinal barrier and the diffusion coefficient on fluorescein in the vitreous with aging in normal subjects. J. Jpn. Ophthalmol. Soc. 1986, 90:589-594.
263. Yoshida A., Ohno-Matsui K., Yasuzumi K., Kojima A., Shimada N., Futagami S., Tokoro T., Mochizuki M. Myopic choroidal neovascularization: a 10-year follow up. Ophthalmology 2003, 110:1297-1305.
264. Yoshida T., Ohno-Matsui K., Ohtake Y. Long-term Visual Prognosis of Choroidal Neovascularization in High Myopia: Comparison Between Age Groups 2002, Ophthalmology 109, 712-719.
265. Young T.L. Dissecting the genetics of human high myopia: a molecular biologic approach. Trans. Am. Ophthalmol. Soc. 2004, 102:423-445.
266. Zolf R., Glacet-Bernard A., Benhamou N., Mimoun G., Coscas G., Soubrane G. Imaging analysis with optical coherence tomography. Relevance for submacular surgery in high myopia and in multifocal choroiditis. Retina 2002, 22:192-201.